The serine protease inhibitor camostat, which is a registered drug in Japan for gastroenterology problems, inhibits TMPRSS2 and confers partial resistance to infection with SARS‐CoV‐2, and total protection when combined with E‐64d, an inhibitor of CatB/L (Hoffmann et al., 2020). Here, TMPRSS2 is linked to infection.